{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T07:03:23Z","timestamp":1789023803059,"version":"build-2803163510"},"reference-count":54,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Lower-risk myelodysplastic syndromes (MDS) are characterized by the presence of dysplasia, low bone marrow blast percentage, low number and depth of cytopenia(s), and relatively good-risk karyotpic and molecular abnormalities. A score of \u22643.5 on the Revised International Prognostic Scoring System classifies patients as lower-risk MDS. Information from a mutational profile of the MDS at time of diagnosis (and over serial time points) can be reassuring for predicted behavior of lower-risk MDS compared with one expected to progress more rapidly (higher-risk MDS). Supportive care continues to be the crux of treatment, although the options to reduce transfusion needs have improved in 2020. Erythropoiesis stimulating agents, lenalidomide, and luspatercept address the most frequent (and symptomatic) cytopenia (anemia) and are started only when patients are transfusion dependent. Patients can derive long-term benefits (years) from these approaches but will often progress to higher-risk MDS. Interestingly, some patients with lower-risk MDS can present with an isolated thrombocytopenia for which thrombopoietin receptor analogs such as romiplostim and eltrombopag are options (as long as blast counts are low). The presence of pancytopenia and or intensifying and unremitting clinical symptoms are often treated with hypomethylating agents or (anti\u2013thymocyte globulin if hypocellular MDS is of concern). Targeted therapies are emerging for small subsets of MDS patients with specific somatic mutations (ie, TP53, IDH1\/2, FLT3), although currently, there are no approved, mutation-directed medications to treat MDS.<\/jats:p>","DOI":"10.1182\/hematology.2020000127","type":"journal-article","created":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T22:18:27Z","timestamp":1607120307000},"page":"426-433","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":55,"title":["Therapy for lower-risk MDS"],"prefix":"10.1182","volume":"2020","author":[{"given":"Hetty E.","family":"Carraway","sequence":"first","affiliation":[{"name":"Leukemia Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caner","family":"Saygin","sequence":"additional","affiliation":[{"name":"Wexner Medical Center, The Ohio State University, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"20","key":"2020121621164206500_B1","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia [published correction in Blood. 2016:128(3):462-463]","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"5","key":"2020121621164206500_B2","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.blre.2018.03.002","article-title":"To chelate or not to chelate in MDS: That is the question!","volume":"32","author":"Zeidan","year":"2018","journal-title":"Blood Rev"},{"issue":"6","key":"2020121621164206500_B3","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"issue":"12","key":"2020121621164206500_B4","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"issue":"27","key":"2020121621164206500_B5","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1200\/JCO.2011.40.7379","article-title":"Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes","volume":"30","author":"Bejar","year":"2012","journal-title":"J Clin Oncol"},{"issue":"23","key":"2020121621164206500_B6","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1182\/blood.V126.23.907.907","article-title":"Somatic mutations in MDS patients are associated with clinical features and predict prognosis independent of the IPSS-R: analysis of combined datasets from the International Working Group for Prognosis in MDS-Molecular Committee","volume":"126","author":"Bejar","year":"2015","journal-title":"Blood"},{"issue":"2","key":"2020121621164206500_B7","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1182\/blood-2015-03-633537","article-title":"SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts","volume":"126","author":"Malcovati","year":"2015","journal-title":"Blood"},{"issue":"12","key":"2020121621164206500_B8","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1038\/leu.2017.266","article-title":"Adding molecular data to prognostic models can improve predictive power in treated patients with myelodysplastic syndromes","volume":"31","author":"Nazha","year":"2017","journal-title":"Leukemia"},{"issue":"2","key":"2020121621164206500_B9","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.blre.2017.10.001","article-title":"What can we learn from ineffective erythropoiesis in thalassemia?","volume":"32","author":"Oikonomidou","year":"2018","journal-title":"Blood Rev"},{"issue":"2","key":"2020121621164206500_B10","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.hoc.2017.11.009","article-title":"Ineffective erythropoiesis: anemia and iron overload","volume":"32","author":"Gupta","year":"2018","journal-title":"Hematol Oncol Clin North Am"},{"issue":"2","key":"2020121621164206500_B11","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"issue":"10","key":"2020121621164206500_B12","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1182\/blood-2018-06-857102","article-title":"Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials","volume":"133","author":"Platzbecker","year":"2019","journal-title":"Blood"},{"issue":"6","key":"2020121621164206500_B13","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1046\/j.1365-2141.2003.04153.x","article-title":"A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life","volume":"120","author":"Hellstr\u00f6m-Lindberg","year":"2003","journal-title":"Br J Haematol"},{"issue":"12","key":"2020121621164206500_B14","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1182\/blood-2009-03-211797","article-title":"Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996)","volume":"114","author":"Greenberg","year":"2009","journal-title":"Blood"},{"issue":"12","key":"2020121621164206500_B15","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1038\/s41375-018-0118-9","article-title":"A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-\u03b1 in anemic patients with low-risk MDS","volume":"32","author":"Fenaux","year":"2018","journal-title":"Leukemia"},{"issue":"5","key":"2020121621164206500_B16","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1365-2141.2006.06070.x","article-title":"High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study","volume":"133","author":"Mannone","year":"2006","journal-title":"Br J Haematol"},{"issue":"10","key":"2020121621164206500_B17","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/S1470-2045(17)30615-0","article-title":"Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study","volume":"18","author":"Platzbecker","year":"2017","journal-title":"Lancet Oncol"},{"issue":"14","key":"2020121621164206500_B18","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1200\/JCO.2016.71.3271","article-title":"Outcome of lower-risk patients with myelodysplastic syndromes without 5q deletion after failure of erythropoiesis-stimulating agents","volume":"35","author":"Park","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"2020121621164206500_B19","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1182\/blood.V92.1.68.413k23_68_75","article-title":"Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients","volume":"92","author":"Hellstr\u00f6m-Lindberg","year":"1998","journal-title":"Blood"},{"issue":"8","key":"2020121621164206500_B20","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1182\/blood-2008-02-139824","article-title":"Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS","volume":"112","author":"Zhou","year":"2008","journal-title":"Blood"},{"issue":"2","key":"2020121621164206500_B21","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa1908892","article-title":"Luspatercept in patients with lower-risk myelodysplastic syndromes","volume":"382","author":"Fenaux","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"2020121621164206500_B22","doi-asserted-by":"crossref","first-page":"513","DOI":"10.7326\/M19-0916","article-title":"Iron chelation in transfusion-dependent patients with low- to intermediate-1-risk myelodysplastic syndromes: a randomized trial","volume":"172","author":"Angelucci","year":"2020","journal-title":"Ann Intern Med"},{"issue":"4","key":"2020121621164206500_B23","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1182\/blood.V98.4.958","article-title":"Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes","volume":"98","author":"Raza","year":"2001","journal-title":"Blood"},{"issue":"6","key":"2020121621164206500_B24","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa041668","article-title":"Efficacy of lenalidomide in myelodysplastic syndromes","volume":"352","author":"List","year":"2005","journal-title":"N Engl J Med"},{"issue":"14","key":"2020121621164206500_B25","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJMoa061292","article-title":"Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion","volume":"355","author":"List","year":"2006","journal-title":"N Engl J Med"},{"issue":"5","key":"2020121621164206500_B26","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/leu.2013.305","article-title":"Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS [published correction in Leukemia. 2015;29:2452]","volume":"28","author":"List","year":"2014","journal-title":"Leukemia"},{"issue":"14","key":"2020121621164206500_B27","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1182\/blood-2011-01-330126","article-title":"A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-\/Intermediate-1-risk myelodysplastic syndromes with del5q","volume":"118","author":"Fenaux","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2020121621164206500_B28","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1182\/blood-2007-01-068833","article-title":"Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q","volume":"111","author":"Raza","year":"2008","journal-title":"Blood"},{"issue":"25","key":"2020121621164206500_B29","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1200\/JCO.2015.66.0118","article-title":"Randomized phase III study of lenalidomide versus placebo in RBC transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes and ineligible for or refractory to erythropoiesis-stimulating agents","volume":"34","author":"Santini","year":"2016","journal-title":"J Clin Oncol"},{"issue":"12","key":"2020121621164206500_B30","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1158\/0008-5472.CAN-15-1756","article-title":"Lenalidomide stabilizes the erythropoietin receptor by inhibiting the E3 ubiquitin ligase RNF41","volume":"76","author":"Basiorka","year":"2016","journal-title":"Cancer Res"},{"issue":"12","key":"2020121621164206500_B31","doi-asserted-by":"crossref","first-page":"e114249","DOI":"10.1371\/journal.pone.0114249","article-title":"Lenalidomide induces lipid raft assembly to enhance erythropoietin receptor signaling in myelodysplastic syndrome progenitors","volume":"9","author":"McGraw","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"2020121621164206500_B32","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/leu.2015.296","article-title":"Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion","volume":"30","author":"Toma","year":"2016","journal-title":"Leukemia"},{"issue":"suppl 1","key":"2020121621164206500_B33","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1182\/blood-2019-127274","article-title":"Combined treatment with lenalidomide and epoetin alfa leads to durable responses in patients with Epo-refractory, lower risk non-deletion 5q [Del(5q)] MDS: final results of the E2905 intergroup phase III study: an ECOG-ACRIN Cancer Research Group study","volume":"134","author":"List","year":"2019","journal-title":"Blood."},{"issue":"6","key":"2020121621164206500_B34","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s00277-016-2649-3","article-title":"Causes of death in 2877 patients with myelodysplastic syndromes","volume":"95","author":"Nachtkamp","year":"2016","journal-title":"Ann Hematol"},{"issue":"12","key":"2020121621164206500_B35","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/cncr.28663","article-title":"Results of a randomized, double-blind study of romiplostim versus placebo in patients with low\/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia","volume":"120","author":"Giagounidis","year":"2014","journal-title":"Cancer"},{"issue":"3","key":"2020121621164206500_B36","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1016\/S2352-3026(18)30016-4","article-title":"Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial","volume":"5","author":"Kantarjian","year":"2018","journal-title":"Lancet Haematol"},{"issue":"3","key":"2020121621164206500_B37","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/S2352-3026(17)30012-1","article-title":"Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial","volume":"4","author":"Oliva","year":"2017","journal-title":"Lancet Haematol"},{"issue":"8","key":"2020121621164206500_B38","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1182\/blood-2002-11-3325","article-title":"A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome","volume":"102","author":"Saunthararajah","year":"2003","journal-title":"Blood"},{"issue":"3","key":"2020121621164206500_B39","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1200\/JCO.2010.31.2686","article-title":"Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care: SAKK 33\/99","volume":"29","author":"Passweg","year":"2011","journal-title":"J Clin Oncol"},{"issue":"7","key":"2020121621164206500_B40","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.3324\/haematol.2012.083345","article-title":"A phase II multicenter rabbit anti-thymocyte globulin trial in patients with myelodysplastic syndromes identifying a novel model for response prediction","volume":"99","author":"Komrokji","year":"2014","journal-title":"Haematologica"},{"issue":"14","key":"2020121621164206500_B41","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1182\/bloodadvances.2018019414","article-title":"The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort","volume":"2","author":"Stahl","year":"2018","journal-title":"Blood Adv"},{"issue":"8","key":"2020121621164206500_B42","doi-asserted-by":"crossref","first-page":"918","DOI":"10.3324\/haematol.2015.140988","article-title":"A randomized phase II trial of azacitidine +\/- epoetin-\u03b2 in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents","volume":"101","author":"Th\u00e9pot","year":"2016","journal-title":"Haematologica"},{"issue":"3","key":"2020121621164206500_B43","doi-asserted-by":"crossref","first-page":"e189","DOI":"10.1038\/bcj.2014.8","article-title":"Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: results from the nordic NMDSG08A phase II trial","volume":"4","author":"Tobiasson","year":"2014","journal-title":"Blood Cancer J"},{"issue":"13","key":"2020121621164206500_B44","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1182\/blood-2017-06-788497","article-title":"Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS\/MPN","volume":"130","author":"Jabbour","year":"2017","journal-title":"Blood"},{"issue":"13","key":"2020121621164206500_B45","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1182\/blood-2016-06-724500","article-title":"Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel","volume":"129","author":"de Witte","year":"2017","journal-title":"Blood"},{"issue":"suppl 1","key":"2020121621164206500_B46","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1182\/blood-2019-128714","article-title":"Roxadustat (FG4592; ASP1517; AZD9941) in the treatment of anemia in patients with lower risk myelodysplastic syndrome (LR-MDS) and low red blood cell (RBC) transfusion burden (LTB)","volume":"134","author":"Henry","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"2020121621164206500_B47","article-title":"Imerge: a study to evaluate imetelstat (GRN163L) in transfusion-dependent subjects with IPSS low or intermediate-1 risk myelodysplastic syndromes (MDS) that is relapsed\/refractory to erythropoiesis-stimulating agent (ESA) treatment","volume":"134","author":"Platzbecker","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"2020121621164206500_B48","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/01.HS9.0000561628.96745.54","article-title":"Treatment with imetelstat provides durable transfusion independence (TI) in heavily transfused non-del(5q) lower risk MDS (LR-MDS) relapsed\/refractory (R\/R) to erythropoiesis stimulating agents (ESAs)","volume":"3","author":"Fenaux","year":"2019","journal-title":"HemaSphere"},{"issue":"suppl 1","key":"2020121621164206500_B49","article-title":"Results of a clinical trial of H3B-8800, a splicing modulator, in patients with myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) or chronic myelomonocytic leukemia (CMML)","volume":"134","author":"Steensma","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"2020121621164206500_B50","article-title":"APR-246 combined with azacitidine (AZA) in TP53 mutated myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). a phase 2 study by the Groupe Francophone Des My\u00e9lodysplasies (GFM)","volume":"134","author":"Cluzeau","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"2020121621164206500_B51","article-title":"Phase 2 results of APR-246 and azacitidine (AZA) in patients with TP53 mutant myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia (AML)","volume":"134","author":"Sallman","year":"2019","journal-title":"Blood"},{"issue":"25","key":"2020121621164206500_B52","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N Engl J Med."},{"issue":"15 suppl","key":"2020121621164206500_B53","article-title":"A phase 1 dose escalation study of the IDH1m inhibitor, FT-2102, in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)","volume":"36","author":"Watts","year":"2018","journal-title":"J Clin Oncol."},{"issue":"6","key":"2020121621164206500_B54","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2020\/1\/426\/1794886\/hem2020000127c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2020\/1\/426\/1794886\/hem2020000127c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T13:12:41Z","timestamp":1608297161000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2020\/1\/426\/474325\/Therapy-for-lowerrisk-MDS"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,4]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12,4]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2020000127","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,4]]}}}